On March 14, 2023 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that it will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL (Press release, Sensei Biotherapeutics, MAR 14, 2023, View Source [SID1234628661]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment
Presentation Type: Poster
Session Category: Tumor Biology
Session Title: Inflammation and Tumor Progression
Date and time: Tuesday, April 18, 2023 1:30 PM – 5:00 p.m. ET
Location: Poster Section 5
The abstract will be available online on the AACR (Free AACR Whitepaper) Online Program Planner. The poster will be made available on the Sensei Bio website following the presentation.